Clinical validation of a novel in vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosis
The CE-marked Atellica<sup>®</sup> IM NfL assay is now validated for prognostic use in RMS patients.
Authors
- M. Gee (ORCID: https://orcid.org/0009-0005-3931-0625)
- Meghana Karnik‐Henry (ORCID: https://orcid.org/0000-0002-2981-7837)
- Xavier Montalbán (ORCID: https://orcid.org/0000-0002-0098-9918)
- Heinz Wiendl (ORCID: https://orcid.org/0000-0003-4310-3432)
- Stefan Bittner (ORCID: https://orcid.org/0000-0003-2179-3655)
- Petra Kukkaro
- Tanuja Chitnis (ORCID: https://orcid.org/0000-0002-9897-4422)
- Dieter A. Häring (ORCID: https://orcid.org/0000-0001-5690-8710)
- Charlotte Elisabeth Teunissen (ORCID: https://orcid.org/0000-0002-4061-0837)
- Amit Bar‐Or (ORCID: https://orcid.org/0000-0001-7179-0335)
- Stephen L. Hauser (ORCID: https://orcid.org/0000-0002-4932-4001)
- Mark S. Freedman
- Martin Merschhemke
- Bernd C. Kieseier
- Sascha Lange
- Tjalf Ziemssen (ORCID: https://orcid.org/0000-0001-8799-8202)
- Eddine Merabet
Institutions
- Universitat de Vic - Universitat Central de Catalunya (ES)
- Universitat Autònoma de Barcelona (ES)
- Brigham and Women's Hospital (US)
- Novartis (Switzerland) (CH)
- Harvard University (US)
- University of Ottawa (CA)
- University of California, San Francisco (US)
- Johannes Gutenberg University Mainz (DE)
- Ottawa Hospital (CA)
- University Medical Center Freiburg (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Amsterdam Neuroscience (NL)
- Siemens Healthcare (United States) (US)
- University Hospital Carl Gustav Carus (DE)
- Technische Universität Dresden (DE)
- University of Pennsylvania (US)
Publication Details
- Journal
- Multiple Sclerosis Journal
- Published
- 2025-10-29
- DOI
- https://doi.org/10.1177/13524585251389797
- Citations
- 2
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.94
Funders
- U.S. Department of Defense
- National Multiple Sclerosis Society
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Alexion Pharmaceuticals
- Celgene
- F. Hoffmann-La Roche
- Novartis Pharmaceuticals Corporation
- European Committee for Treatment and Research in Multiple Sclerosis
- TG Therapeutics
- Atara Biotherapeutics
- Mylan
- Multiple Sclerosis Society
- European Commission
- Bayer HealthCare
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung
- Gemeinnützige Hertie-Stiftung
- Eisai
- Multiple Sclerosis International Federation
- Schweizerische Multiple Sklerose Gesellschaft
- Siemens Healthineers
- Neuraxpharm
- Grifols
- MedDay Pharmaceuticals
- National Institutes of Health
- Genentech
- Samsung
- EMD Serono
- Novartis Pharma
- Janssen Pharmaceuticals